247 related articles for article (PubMed ID: 17482743)
1. Formation and persistence of DNA adducts of anticancer drug ellipticine in rats.
Stiborová M; Rupertová M; Aimová D; Ryslavá H; Frei E
Toxicology; 2007 Jul; 236(1-2):50-60. PubMed ID: 17482743
[TBL] [Abstract][Full Text] [Related]
2. The anticancer drug ellipticine is a potent inducer of rat cytochromes P450 1A1 and 1A2, thereby modulating its own metabolism.
Aimová D; Svobodová L; Kotrbová V; Mrázová B; Hodek P; Hudecek J; Václavíková R; Frei E; Stiborová M
Drug Metab Dispos; 2007 Oct; 35(10):1926-34. PubMed ID: 17656468
[TBL] [Abstract][Full Text] [Related]
3. Rat microsomes activating the anticancer drug ellipticine to species covalently binding to deoxyguanosine in DNA are a suitable model mimicking ellipticine bioactivation in humans.
Stiborová M; Stiborová-Rupertová M; Borek-Dohalská L; Wiessler M; Frei E
Chem Res Toxicol; 2003 Jan; 16(1):38-47. PubMed ID: 12693029
[TBL] [Abstract][Full Text] [Related]
4. Role of hepatic cytochromes P450 in bioactivation of the anticancer drug ellipticine: studies with the hepatic NADPH:cytochrome P450 reductase null mouse.
Stiborová M; Arlt VM; Henderson CJ; Wolf CR; Kotrbová V; Moserová M; Hudecek J; Phillips DH; Frei E
Toxicol Appl Pharmacol; 2008 Feb; 226(3):318-27. PubMed ID: 17976674
[TBL] [Abstract][Full Text] [Related]
5. DNA adduct formation by the anticancer drug ellipticine in rats determined by 32P postlabeling.
Stiborová M; Breuer A; Aimová D; Stiborová-Rupertová M; Wiessler M; Frei E
Int J Cancer; 2003 Dec; 107(6):885-90. PubMed ID: 14601046
[TBL] [Abstract][Full Text] [Related]
6. The mechanism of cytotoxicity and DNA adduct formation by the anticancer drug ellipticine in human neuroblastoma cells.
Poljaková J; Eckschlager T; Hrabeta J; Hrebacková J; Smutný S; Frei E; Martínek V; Kizek R; Stiborová M
Biochem Pharmacol; 2009 May; 77(9):1466-79. PubMed ID: 19426684
[TBL] [Abstract][Full Text] [Related]
7. Role of cytochromes P450 and peroxidases in metabolism of the anticancer drug ellipticine: additional evidence of their contribution to ellipticine activation in rat liver, lung and kidney.
Stiborova M; Moserova M; Mrazova B; Kotrbova V; Frei E
Neuro Endocrinol Lett; 2010; 31 Suppl 2():26-35. PubMed ID: 21187821
[TBL] [Abstract][Full Text] [Related]
8. The anticancer drug ellipticine forms covalent DNA adducts, mediated by human cytochromes P450, through metabolism to 13-hydroxyellipticine and ellipticine N2-oxide.
Stiborová M; Sejbal J; Borek-Dohalská L; Aimová D; Poljaková J; Forsterová K; Rupertová M; Wiesner J; Hudecek J; Wiessler M; Frei E
Cancer Res; 2004 Nov; 64(22):8374-80. PubMed ID: 15548707
[TBL] [Abstract][Full Text] [Related]
9. Oxidation pattern of the anticancer drug ellipticine by hepatic microsomes - similarity between human and rat systems.
Stiborová M; Borek-Dohalská L; Aimová D; Kotrbová V; Kukacková K; Janouchová K; Rupertová M; Ryslavá H; Hudecek J; Frei E
Gen Physiol Biophys; 2006 Sep; 25(3):245-61. PubMed ID: 17197724
[TBL] [Abstract][Full Text] [Related]
10. Mammalian peroxidases activate anticancer drug ellipticine to intermediates forming deoxyguanosine adducts in DNA identical to those found in vivo and generated from 12-hydroxyellipticine and 13-hydroxyellipticine.
Stiborová M; Poljaková J; Ryslavá H; Dracínský M; Eckschlager T; Frei E
Int J Cancer; 2007 Jan; 120(2):243-51. PubMed ID: 17066455
[TBL] [Abstract][Full Text] [Related]
11. Formation, persistence, and identification of DNA adducts formed by the carcinogenic environmental pollutant o-anisidine in rats.
Naiman K; Dracínský M; Hodek P; Martínková M; Schmeiser HH; Frei E; Stiborová M
Toxicol Sci; 2012 Jun; 127(2):348-59. PubMed ID: 22403159
[TBL] [Abstract][Full Text] [Related]
12. Cytotoxicity of and DNA adduct formation by ellipticine in human U87MG glioblastoma cancer cells.
Martinkova E; Dontenwill M; Frei E; Stiborova M
Neuro Endocrinol Lett; 2009; 30 Suppl 1():60-6. PubMed ID: 20027146
[TBL] [Abstract][Full Text] [Related]
13. DNA adduct formation by the anticancer drug ellipticine in human leukemia HL-60 and CCRF-CEM cells.
Poljaková J; Frei E; Gomez JE; Aimová D; Eckschlager T; Hrabeta J; Stiborová M
Cancer Lett; 2007 Jul; 252(2):270-9. PubMed ID: 17306925
[TBL] [Abstract][Full Text] [Related]
14. Cytochromes P450 reconstituted with NADPH: P450 reductase mimic the activating and detoxicating metabolism of the anticancer drug ellipticine in microsomes.
Kotrbová V; Aimová D; Brezinová A; Janouchová K; Poljaková J; Frei E; Stiborová M
Neuro Endocrinol Lett; 2006 Dec; 27 Suppl 2():18-22. PubMed ID: 17159771
[TBL] [Abstract][Full Text] [Related]
15. Anticancer agent ellipticine combined with histone deacetylase inhibitors, valproic acid and trichostatin A, is an effective DNA damage strategy in human neuroblastoma.
Poljakova J; Hrebackova J; Dvorakova M; Moserova M; Eckschlager T; Hrabeta J; Göttlicherova M; Kopejtkova B; Frei E; Kizek R; Stiborova M
Neuro Endocrinol Lett; 2011; 32 Suppl 1():101-16. PubMed ID: 22167207
[TBL] [Abstract][Full Text] [Related]
16. Analysis of covalent ellipticine- and doxorubicin-derived adducts in DNA of neuroblastoma cells by the ³²P-postlabeling technique.
Stiborova M; Poljakova J; Eckschlager T; Kizek R; Frei E
Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub; 2012 Jun; 156(2):115-21. PubMed ID: 22837132
[TBL] [Abstract][Full Text] [Related]
17. Oxidation of an antitumor drug ellipticine by peroxidases.
Poljaková J; Forsterová K; Sulc M; Frei E; Stiborová M
Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub; 2005 Dec; 149(2):449-53. PubMed ID: 16601808
[TBL] [Abstract][Full Text] [Related]
18. Persistence of platinum-ammine-DNA adducts in gonads and kidneys of rats and multiple tissues from cancer patients.
Poirier MC; Reed E; Litterst CL; Katz D; Gupta-Burt S
Cancer Res; 1992 Jan; 52(1):149-53. PubMed ID: 1727376
[TBL] [Abstract][Full Text] [Related]
19. Ochratoxin a causes DNA damage and cytogenetic effects but no DNA adducts in rats.
Mally A; Pepe G; Ravoori S; Fiore M; Gupta RC; Dekant W; Mosesso P
Chem Res Toxicol; 2005 Aug; 18(8):1253-61. PubMed ID: 16097798
[TBL] [Abstract][Full Text] [Related]
20. The formation and persistence of carboplatin-DNA adducts in rats.
Blommaert FA; Michael C; van Dijk-Knijnenburg HC; Schornagel JH; den Engelse L; Fichtinger-Schepman AM
Cancer Chemother Pharmacol; 1996; 38(3):273-80. PubMed ID: 8646803
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
